Psychostimulant addiction treatment
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Treatment of psychostimulant addiction has been a major, and not fully met, challenge. For opioid addiction, there is strong evidence for the effectiveness of several medications. For psychostimulants, there is no corresponding form of agonist maintenance that has met criteria for regulatory approval or generally accepted use. Stimulant-use disorders remain prevalent and can result in both short-term and long-term adverse consequences. The mainstay of treatment remains behavioral interventions. In this paper, we discuss those interventions and some promising candidates in the search for pharmacological interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular and molecular mechanisms of drug dependence
Koob, G. F., & Bloom, F. E. (1988) · Science · doi:10.1126/science.2903550 · Cited by 2,070
The incentive sensitization theory of addiction: some current issues
Robinson, T. E., & Berridge, K. C. (2008) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2008.0093 · Cited by 1,717 · cited 1×
“Most current theories of addiction that attempt to account for psychostimulant addiction emphasize the primary role of conditioned craving, which can persist long after physiological withdrawal has abated (Robinson & Berridge, 2008).”
BackgroundA Meta-Analytic Review of Psychosocial Interventions for Substance Use Disorders
Dutra, L., Stathopoulou, G., Basden, S. L., Leyro, T. M., Powers, M. B., & Otto, M. W. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111851 · Cited by 1,287
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
THE BEHAVIOR OF CHILDREN RECEIVING BENZEDRINE
Bradley, C. (1937) · American Journal of Psychiatry · doi:10.1176/ajp.94.3.577 · Cited by 1,035
Practice Parameters for the Treatment of Narcolepsy and other Hypersomnias of Central Origin
Morgenthaler, T. I., Kapur, V. K., Brown, T. M., Swick, T. J., Alessi, C., Aurora, R. N., Boehlecke, B., Chesson, A. L., Friedman, L., Maganti, R., et al. (2007) · Sleep · doi:10.1093/sleep/30.12.1705 · Cited by 488 · cited 1×
“Some psychostimulants, including methylphenidate, amphetamine, and methamphetamine are approved in the US for treatment of Attention Deficit Hyperactivity Disorder (ADHD) (Dopheide & Pliszka, 2009), weight control (Greenway & Caruso, 2005), and narcolepsy (Morgenthaler et al., 2007).”
BackgroundA Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300600 · Cited by 391 · cited 3×
“However, more recent clinical trials in patients with cocaine-use disorder (Dackis et al., 2012) or methamphetamine-use disorder (Anderson et al.”
BackgroundMethodRelapse prevention as a psychosocial treatment: A review of controlled clinical trials.
Carroll, K. M. (1996) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.4.1.46 · Cited by 285
Dextroamphetamine for Cocaine-Dependence Treatment: A Double-Blind Randomized Clinical Trial
Grabowski, J., Rhoades, H., Schmitz, J., Stotts, A., Daruzska, L. A., Creson, D., & Moeller, F. G. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00010 · Cited by 243 · cited 2×
“Early clinical studies showed that d-amphetamine improved retention in treatment and reduced illicit cocaine use (Grabowski et al., 2001).”
BackgroundMethodBupropion for the treatment of methamphetamine dependence
Elkashef, A. M., Rawson, R. A., Anderson, A. L., Li, S.-H., Holmes, T., Smith, E. V., Chiang, N., Kahn, R., Vocci, F., Ling, W., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301481 · Cited by 234 · cited 5×
“Elkashef et al., 2008 Double-blind placebo-controlled randomized clinical trial: bupropion vs. placebo Treatment-seekers with DSM-IV diagnosis of methamphetamine dependence (N=151) in 12 weeks of treatment and a 30- day follow-up To test bupropion for efficacy in increasing weeks of abstinence in…”
BackgroundMethodInfluentialAmphetamine and methamphetamine differentially affect dopamine transporters in vitro and in vivo.
Goodwin, J. S., Larson, G. A., Swant, J., Sen, N., Javitch, J. A., Zahniser, N. R., De Felice, L. J., & Khoshbouei, H. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m805298200 · Cited by 203 · cited 2×
“Methamphetamine is more potent and more efficacious than amphetamine, producing much higher concentrations of synaptic dopamine (Goodwin et al., 2009) and more toxic effects on nerve terminals (Carvalho et al.”
BackgroundStimulant Abuse: Pharmacology, Cocaine, Methamphetamine, Treatment, Attempts at Pharmacotherapy
Ciccarone, D. (2011) · Primary Care: Clinics in Office Practice · doi:10.1016/j.pop.2010.11.004 · Cited by 200 · cited 2×
“Behavioral therapies, including Cognitive-Behavioral Therapy (CBT), the Community Reinforcement Approach (CRA), contingency management, combinations of these, and others remain the mainstay of treatment for stimulant-use disorders (Carroll, 1996, 1997; Ciccarone, 2011).”
MethodContingency Management for the Treatment of Methamphetamine Use Disorders
Roll, J. M., Petry, N. M., Stitzer, M. L., Brecht, M. L., Peirce, J. M., McCann, M. J., Blaine, J., MacDonald, M., DiMaria, J., Lucero, L., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.11.1993 · Cited by 196
A double-blind, placebo-controlled trial of modafinil for cocaine dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Plebani, J. G., Pettinati, H. M., Sparkman, T., & O'Brien, C. P. (2012) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2011.12.014 · Cited by 187
Maude-Griffin, P. M., Hohenstein, J. M., Humfleet, G. L., Reilly, P. M., Tusel, D. J., & Hall, S. M. (1998) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.66.5.832 · Cited by 162
A double‐blind, placebo‐controlled trial of modafinil (200 mg/day) for methamphetamine dependence
Shearer, J., Darke, S., Rodgers, C., Slade, T., Van Beek, I., Lewis, J., Brady, D., McKetin, R., Mattick, R. P., & Wodak, A. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02437.x · Cited by 159 · cited 3×
“, 2012) or methamphetamine-use disorder (Anderson et al., 2012; Shearer et al., 2009) have been equivocal, as have studies of a combination of d-amphetamine and modafinil (Schmitz et al.”
BackgroundMethodEffects of oral methamphetamine on cocaine use: A randomized, double-blind, placebo-controlled trial
Mooney, M. E., Herin, D. V., Schmitz, J. M., Moukaddam, N., Green, C. E., & Grabowski, J. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.10.016 · Cited by 124 · cited 4×
“Mooney et al. (Mooney et al., 2009) tested it as a treatment for cocaine-use disorder in a randomized, double-blind, placebo-controlled study and found that it was well-tolerated and that it reduced cocaine craving and rates of cocaine-positive urine samples.”
BackgroundMethodInfluentialCoffey, S. F., Dansky, B. S., Carrigan, M. H., & Brady, K. T. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00126-x · Cited by 120
Pharmacogenetic Randomized Trial for Cocaine Abuse: Disulfiram and Dopamine β-Hydroxylase
Kosten, T. R., Wu, G., Huang, W., Harding, M. J., Hamon, S. C., Lappalainen, J., & Nielsen, D. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.07.011 · Cited by 108 · cited 4×
“Disulfiram may be effective for treatment of cocaine addiction only in individuals with the genotype for normal levels of DBH (Kosten et al., 2013).”
BackgroundInfluentialA placebo‐controlled trial of mirtazapine for the management of methamphetamine withdrawal
CRUICKSHANK, C. C., MONTEBELLO, M. E., DYER, K. R., QUIGLEY, A., BLASZCZYK, J., TOMKINS, S., & SHAND, D. (2008) · Drug and Alcohol Review · doi:10.1080/09595230801935672 · Cited by 74 · cited 2×
“Cruickshank et al., 2008 Double-blind placebo-controlled randomized clinical trial: mirtazapine vs. placebo 31 participants (18 placebo, 13 mirtazapine) meeting DSM-IV criteria for amphetamine-type stimulant dependence and reported use of amphetamine or methamphetamine during the prior 72 hours;…”
BackgroundMethodDuration effects in contingency management treatment of methamphetamine disorders
Roll, J. M., Chudzynski, J., Cameron, J. M., Howell, D. N., & McPherson, S. (2013) · Addictive Behaviors · doi:10.1016/j.addbeh.2013.03.018 · Cited by 65
Nonmedical use of prescription ADHD stimulants and preexisting patterns of drug abuse
Sweeney, C. T., Sembower, M. A., Ertischek, M. D., Shiffman, S., & Schnoll, S. H. (2013) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.759858 · Cited by 65
Miles, S. W., Sheridan, J., Russell, B., Kydd, R., Wheeler, A., Walters, C., Gamble, G., Hardley, P., Jensen, M., Kuoppasalmi, K., et al. (2013) · Addiction · doi:10.1111/add.12109 · Cited by 63
Sembower, M. A., Ertischek, M. D., Buchholtz, C., Dasgupta, N., & Schnoll, S. H. (2013) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.759880 · Cited by 34
Cited by
Non-invasive Human Brain Stimulation in Cognitive Neuroscience: A Primer
Parkin, B. L., Ekhtiari, H., & Walsh, V. F. (2015) · Neuron · doi:10.1016/j.neuron.2015.07.032 · Cited by 273
Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults
Castells, X., Blanco-Silvente, L., & Cunill, R. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007813.pub3 · Cited by 209
Pharmacotherapy for Cocaine Use Disorder—a Systematic Review and Meta-analysis
Chan, B., Kondo, K., Freeman, M., Ayers, C., Montgomery, J., & Kansagara, D. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05074-8 · Cited by 150
Drug addiction: from bench to bedside
Cheron, J., & Kerchove d’Exaerde, A. D. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01542-0 · Cited by 75
“Clinical treatments for drug addiction Besides psychosocial interventions [211] such as cognitive behavioural therapy, the most widely used treatment for drug addiction involves agonist-like medication, a solution inadequately called replacement or substitution therapy [212].”
BackgroundRisk factors for stimulant use among homeless and unstably housed adult women
Riley, E. D., Shumway, M., Knight, K. R., Guzman, D., Cohen, J., & Weiser, S. D. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.05.023 · Cited by 46
Metadata
- Authors
- Phillips, K. A., Epstein, D. H., & Preston, K. L.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 87
- Pages
- 150-160
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W2093102031
- Cited by
- 75
- References
- 24
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.